Gemcitabine has known activity in sarcoma; although its exact role, indication, or best combination is still debated. The combination of gemcitabine and docetaxel gained favour in the USA after efficacy was noted in uterine leiomyosarcoma^1,2 and later in sarcoma, generally with superiority over gemcitabine alone.³ However, this combination is used to a lesser extent in Europe, partly due to more equivocal data in leiomyosarcoma,⁴ noted efficacy of other gemcitabine-based regimens,⁵ and potential issues of access as described in the GeDDiS⁶ trial in The Lancet Oncology.

中文翻译：

---

GeDDiS：洞察软组织肉瘤的一线治疗

吉西他滨在肉瘤中有已知的活性。尽管其确切的作用，适应症或最佳组合尚有争议。吉西他滨和多西他赛的组合在子宫肌肉瘤^1,2和后来的肉瘤中均注意到疗效后，在美国广受青睐，通常优于单独使用吉西他滨。³然而，在欧洲使用这种组合的程度较低，部分原因是平滑肌肉瘤的数据更加模棱两可，⁴指出了其他基于吉西他滨的治疗方案的疗效，⁵以及《柳叶刀肿瘤》杂志上的GeDDiS ⁶试验中所述的潜在的获取问题。。